1140 related articles for article (PubMed ID: 15182221)
1. Interferon-beta-1b: a review of its use in relapsing-remitting and secondary progressive multiple sclerosis.
McCormack PL; Scott LJ
CNS Drugs; 2004; 18(8):521-46. PubMed ID: 15182221
[TBL] [Abstract][Full Text] [Related]
2. Spotlight on Interferon-beta-1b in relapsing-remitting and secondary progressive multiple sclerosis.
McCormack PL; Scott LJ
BioDrugs; 2004; 18(5):343-7. PubMed ID: 15377176
[TBL] [Abstract][Full Text] [Related]
3. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
4. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.
Goldberg LD; Edwards NC; Fincher C; Doan QV; Al-Sabbagh A; Meletiche DM
J Manag Care Pharm; 2009 Sep; 15(7):543-55. PubMed ID: 19739877
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
Cochrane Database Syst Rev; 2013 Jun; (6):CD008933. PubMed ID: 23744561
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis.
Sanford M; Lyseng-Williamson KA
Drugs; 2011 Oct; 71(14):1865-91. PubMed ID: 21942977
[TBL] [Abstract][Full Text] [Related]
7. Interferon-β-1b: a review of its use in multiple sclerosis.
Plosker GL
CNS Drugs; 2011 Jan; 25(1):67-88. PubMed ID: 21128695
[TBL] [Abstract][Full Text] [Related]
8. Interferon beta-1b (betaseron/betaferon) is well tolerated at a dose of 500 microg: interferon dose escalation assessment of safety (IDEAS).
Gottesman MH; Friedman-Urevich S
Mult Scler; 2006 Jun; 12(3):271-80. PubMed ID: 16764339
[TBL] [Abstract][Full Text] [Related]
9. Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis.
Andersen O; Elovaara I; Färkkilä M; Hansen HJ; Mellgren SI; Myhr KM; Sandberg-Wollheim M; Soelberg Sørensen P
J Neurol Neurosurg Psychiatry; 2004 May; 75(5):706-10. PubMed ID: 15090564
[TBL] [Abstract][Full Text] [Related]
10. Interferon beta for secondary progressive multiple sclerosis.
La Mantia L; Vacchi L; Di Pietrantonj C; Ebers G; Rovaris M; Fredrikson S; Filippini G
Cochrane Database Syst Rev; 2012 Jan; 1():CD005181. PubMed ID: 22258960
[TBL] [Abstract][Full Text] [Related]
11. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
Nikfar S; Rahimi R; Abdollahi M
Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data.
Bell C; Graham J; Earnshaw S; Oleen-Burkey M; Castelli-Haley J; Johnson K
J Manag Care Pharm; 2007 Apr; 13(3):245-61. PubMed ID: 17407391
[TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability of a 'refrigeration-free' formulation of interferon beta-1b--results of a double-blind, multicentre, comparative study in patients with relapsing-remitting or secondary progressive multiple sclerosis.
Baum K;
J Int Med Res; 2006; 34(1):1-12. PubMed ID: 16604818
[TBL] [Abstract][Full Text] [Related]
14. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis.
Simpson D; Noble S; Perry C
CNS Drugs; 2002; 16(12):825-50. PubMed ID: 12421116
[TBL] [Abstract][Full Text] [Related]
15. The Danish National Project of interferon-beta treatment in relapsing-remitting multiple sclerosis. The Danish Multiple Sclerosis Group.
Koch-Henriksen N; Sørensen PS
Mult Scler; 2000 Jun; 6(3):172-5. PubMed ID: 10871828
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of interferons in relapsing-remitting multiple sclerosis: a meta-analysis of real-world studies.
Einarson TR; Bereza BG; Machado M
Curr Med Res Opin; 2017 Mar; 33(3):579-593. PubMed ID: 28027680
[TBL] [Abstract][Full Text] [Related]
17. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
[TBL] [Abstract][Full Text] [Related]
18. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.
Panitch H; Miller A; Paty D; Weinshenker B;
Neurology; 2004 Nov; 63(10):1788-95. PubMed ID: 15557491
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS.
Clanet M; Radue EW; Kappos L; Hartung HP; Hohlfeld R; Sandberg-Wollheim M; Kooijmans-Coutinho MF; Tsao EC; Sandrock AW;
Neurology; 2002 Nov; 59(10):1507-17. PubMed ID: 12451189
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
